Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure

Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure

Abstract Aim The optimal strategy for diabetes control in patients with heart failure (HF) following myocardial infarction (MI) remains unknown. Metformin, a guideline‐recommended therapy for patients with chronic HF and type 2 diabetes mellitus (T2DM), is associated with reduced mortality and HF ho...

Full description

Bibliographic Details
Main Authors: Thomas R. Godec, Daniel I. Bromage, Mar Pujades‐Rodriguez, Antonio Cannatà, Arturo Gonzalez‐Izquierdo, Spiros Denaxas, Harry Hemingway, Ajay M. Shah, Derek M. Yellon, Theresa A. McDonagh
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:ESC Heart Failure
Subjects:
Heart failure
Ischaemic cardiomyopathy
Metformin
Outcomes
Type 2 diabetes
Antidiabetic agents
Online Access:https://doi.org/10.1002/ehf2.13910

Internet

https://doi.org/10.1002/ehf2.13910

Similar Items